Zhihang Liu

Zhihang Liu

Auto-generated profile, based on publicly available information

Zhihang Liu

Changsha Med Univ, Double Class Applicat Characterist Discipline Huna, Changsha, Peoples R China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2023 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
WLWenfeng Liang
Wenfeng Liang
HLHuashan Liu
Huashan Liu
ZZZiwei Zeng
Ziwei Zeng
ZLZhenxing Liang
Zhenxing Liang
HXHao Xie
Hao Xie
LKLiang Kang
Liang Kang
Poor infiltration of T lymphocytes has been regarded as a crucial mechanism of tumor immune escape. Here, we demonstrate a protective role of KRT17 in colorectal cancer, where KRT17 reversed the tumor immunosuppressive microenvironment by increasing T-lymphocyte infiltration. High-throughput RNA sequencing suggested that KRT17 was significantly upregulated in deficient mismatch repair (dMMR) tumors compared with proficient mismatch repair (pMMR) tumors. In a colorectal cancer cohort of 446 cases, KRT17 expression positively correlated with better clinical outcomes. Krt17 overexpression decreased xenograft tumor growth in immune-competent mice. T-cell depletion in a murine model showed that the presence of T lymphocytes was necessary for Krt17-mediated disruption of tumorigenesis. Mass spectrometry and coimmunoprecipitation assays suggested KRT17 caused YTHDF2 degradation through the ubiquitin-proteasome system. Through high-throughput RNA immunoprecipitation sequencing, we found that CXCL10 was the target gene of the N6-methyladenosine (m6A) “reader” YTHDF2. KRT17 synergized with anti–PD-1 for better tumor control in an immunotherapy-resistant murine model. In a cohort of patients with colorectal cancer receiving pembrolizumab, high KRT17 expression was found within the tumors of responders. Collectively, we elucidated a critical role of KRT17 in colorectal cancer to prevent immune escape. These findings present new insights into potential therapeutic strategies and effective markers of immunotherapy reactivity against pMMR tumors.

6 November 2024 in Experimental Cell Research
Verified
Journal Article
Closed access
ZZZiwei Zeng
Ziwei Zeng
YSYiming Shi
Yiming Shi
YCYonghua Cai
Yonghua Cai
XYXin Yang
Xin Yang
XZXiaobin Zheng
Xiaobin Zheng
WLWenxin Li
Wenxin Li

14 May 2024 in Experimental Cell Research
Verified
Journal Article
Closed access
CLChuangkun Li
Chuangkun Li
JYJianmei Yi
Jianmei Yi
HJHaiqing Jie
Haiqing Jie
ZLZhihang Liu
Zhihang Liu
SLShujuan Li
Shujuan Li
YZYi Zhou
Yi Zhou

16 September 2024
Verified
Other
Open access
WLWenfeng Liang
Wenfeng Liang
HLHuashan Liu
Huashan Liu
ZZZiwei Zeng
Ziwei Zeng
ZLZhenxing Liang
Zhenxing Liang
HXHao Xie
Hao Xie
LKLiang Kang
Liang Kang
Materials were used in the research.

26 November 2025
Verified
Other
Open access
PDF file
WLWenfeng Liang
Wenfeng Liang
HLHuashan Liu
Huashan Liu
ZZZiwei Zeng
Ziwei Zeng
ZLZhenxing Liang
Zhenxing Liang
HXHao Xie
Hao Xie
LKLiang Kang
Liang Kang
KRT17 is highly expressed in CRC tissues compared to tumor-adjacent tissue regardless of MMR status.

26 November 2025
Verified
Other
Open access
WLWenfeng Liang
Wenfeng Liang
HLHuashan Liu
Huashan Liu
ZZZiwei Zeng
Ziwei Zeng
ZLZhenxing Liang
Zhenxing Liang
HXHao Xie
Hao Xie
LKLiang Kang
Liang Kang
Materials were used in the research.